The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.

Department of Clinical Immunology, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
International Journal of Molecular Medicine (Impact Factor: 1.88). 09/2010; 26(3):435-42.
Source: PubMed

ABSTRACT The loss of the CD16a, Fc receptor for IgG type III, (FcgammaRIIIa) B73.1/Leu11c binding epitope, detected by the monoclonal antibody (mAb) used in routine enumeration of NK cells or monocytes, has been observed in children with recurrent viral infections. It has also been linked with the change of leucine (L) to histidine (H) or arginine (R) at amino acid position 48 (FcgammaRIIIa-48L/R/H) in the CD16a receptor. The reactivity of the anti-CD16a clone B73.1/Leu11c mAb with monocytes and NK cells was examined in patients with primary immunodeficiencies (n=167), gastrointestinal malignancies (n=91) and healthy subjects (n=88). Cells of only 12 children, 11 with diagnosed primary immunodeficiency and one with recurrent bacterial infections were not reactive with B73.1/Leu11c mAb. In contrast to previous findings, no linkage between the loss of B73.1/Leu11c binding epitope and herpes virus infections was observed. Furthermore, the sequence analysis of the FcgammaRIIIa gene performed in these 12 patients and 11 healthy subjects revealed that all of them had FcgammaRIIIa-48L/L genotype. Thus, the loss of B73.1/Leu11c binding epitope was not associated with the FcgammaRIIIa-48 polymorphism. The commonly described FcgammaRIIIa-158 polymorphism was determined to be 158V/V in 11 patients and 5 healthy subjects. Moreover, no linkage between FcgammaRIIIa-48L/L and -158F/F genotypes was observed. It is suggested that the loss of the B73.1/Leu11c binding epitope is connected with primary immunodeficiency disorders, but not associated with the FcgammaRIIIa-48 polymorphism.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis has been characterized as an inflammatory process, in which monocytes and monocyte-derived macrophages are of paramount importance. Contrasting with their established role in atherosclerosis, monocytes have not unanimously been found to predict cardiovascular events in large epidemiological studies. However, in these studies human monocyte heterogeneity has been largely overlooked so far. Three human monocyte subsets can be distinguished: classical CD14(++)CD16(-), intermediate CD14(++)CD16(+) and nonclassical CD14(+)CD16(++) monocytes. Of note, correct enumeration of subset counts requires appropriate staining and gating strategies that encompass a pan-monocytic marker (e.g. HLA-DR or CD86). In experimental studies on murine atherogenesis a monocyte subset-specific contribution to atherosclerosis has been established. However, major interspecies differences in atherogenesis itself, as well as in the immune system (including monocyte subset phenotype and distribution) preclude a direct extrapolation to human pathology. Experimental and pilot clinical studies point to a prominent involvement of intermediate CD14(++)CD16(+) monocytes in human atherosclerosis. Future clinical studies should analyze monocyte heterogeneity in cardiovascular disease. If a specific contribution of intermediate monocytes should be confirmed, immunomodulation of this monocyte subset could represent a future therapeutic target in atherosclerosis.
    Immunobiology 07/2012; · 2.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Natural killer (NK) cells are part of the innate immune defense against infection and cancer and are especially useful in combating certain viral pathogens. The utility of NK cells in human health has been underscored by a growing number of persons who are deficient in NK cells and/or their functions. This can be in the context of a broader genetically defined congenital immunodeficiency, of which there are more than 40 presently known to impair NK cells. However, the abnormality of NK cells in certain cases represents the majority immunologic defect. In aggregate, these conditions are termed NK cell deficiency. Recent advances have added clarity to this diagnosis and identified defects in 3 genes that can cause NK cell deficiency, as well as some of the underlying biology. Appropriate consideration of these diagnoses and patients raises the potential for rational therapeutic options and further innovation.
    The Journal of allergy and clinical immunology 09/2013; 132(3):515-25. · 12.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rare human primary immunodeficiency disorders with extreme susceptibility to infections in infancy have provided important insights into immune function. Increasingly, however, primary immunodeficiencies are also recognized as a cause of other more common, often discrete, infectious susceptibilities. In a wider context, loss-of-function mutations in immune genes may also cause disorders of immune regulation and predispose to cancer. Here, we review the associations between human diseases and mutations in genetic elements affecting natural killer (NK) cell development and function. Although many such genetic aberrations significantly reduce NK cell numbers or severely impair NK cell responses, inferences regarding the role of NK cells in disease are confounded by the fact that most mutations also affect the development or function of other cell types. Still, data suggest an important role for NK cells in diseases ranging from classical immunodeficiency syndromes with susceptibility to viruses and other intracellular pathogens to cancer, autoimmunity, and hypersensitivity reactions.
    Cellular and Molecular Life Sciences CMLS 08/2011; 68(21):3479-93. · 5.86 Impact Factor


Available from
Jun 6, 2014